Ipsen: disappointing final data in prostate cancer trial

(CercleFinance.com) - Ipsen reports disappointing final detailed overall survival (OS) data for the CONTACT-02 phase III trial evaluating its Cabometyx in combination with atezolizumab in metastatic castration-resistant prostate cancer (mCPRC).


With a median follow-up of 24 months, they demonstrated a numerical, but not statistically significant, improvement in OS compared with a second NHT (new hormonal therapy), thus missing one of the two primary endpoints.

In view of the regulatory environment in countries where Ipsen holds marketing rights (outside the US and Japan), it has decided not to pursue the regulatory submission process for this regimen in the mCPRC.


Copyright (c) 2024 CercleFinance.com. All rights reserved.